Spots Global Cancer Trial Database for imiquimod
Every month we try and update this database with for imiquimod cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma | NCT01400672 | Diffuse Intrins... | Tumor Lysate Va... Imiquimod Radiation thera... | 3 Years - | Masonic Cancer Center, University of Minnesota | |
| Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia | NCT01861535 | Vulvar Intraepi... | Imiquimod Surgery | 18 Years - 90 Years | Medical University of Graz | |
| Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma | NCT02242929 | Nodular Basal C... | Imiquimod 5% cr... Standard surgic... | 18 Years - 90 Years | Maastricht University Medical Center | |
| Real-world Evaluation of Diagnostic and Treatment Strategies in Low-Risk Basal Cell Carcinoma | NCT06252857 | Basal Cell Carc... | Imiquimod Topic... | 18 Years - | Maastricht University Medical Center | |
| Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses | NCT00774787 | Actinic Keratos... | imiquimod 5% cr... | 18 Years - | Rigel Dermatology | |
| Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor | NCT01171469 | Brain Tumor Glioblastoma Medulloblastoma Ependymoma Anaplastic Astr... | Dendritic Cells Imiquimod | - | Masonic Cancer Center, University of Minnesota | |
| IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis | NCT02281682 | Keratosis, Acti... | Imiquimod 5-fluorouracil Ingenol mebutat... methylaminolevu... | 18 Years - | Maastricht University Medical Center | |
| Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV | NCT01663558 | Anal Dysplasia Human Papilloma... HIV | imiquimod ablative | 18 Years - | United States Naval Medical Center, San Diego | |
| Imiquimod and Actinic Keratoses: an Observational Study | NCT01151956 | Actinic Keratos... | - | Federal University Teaching Hospital, Feldkirch, Austria | ||
| Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin | NCT00453050 | Melanoma (Skin) Metastatic Canc... | imiquimod indocyanine gre... flow cytometry immunologic tec... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Imiquimod Treatment of CIN Lesions | NCT02329171 | Cervical Intrae... | Imiquimod LLETZ | 18 Years - | Maastricht University Medical Center | |
| HER2-Peptide Vaccination of Patients With Solid Tumors | NCT02276300 | Gastric Cancer Breast Cancer | Cyclophosphamid... Sargramostim HER2-Peptid-Vak... Imiquimod | 18 Years - | Technical University of Munich | |
| Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated With Imiquimod | NCT06356012 | HSIL, High-Grad... Vaginal Microbi... Biomarkers | Imiquimod Loop Electrosur... | 25 Years - 45 Years | Barretos Cancer Hospital | |
| Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis | NCT00948428 | Actinic Keratos... | imiquimod Aldara™ Vehicle Cream | 18 Years - | Actavis Inc. | |
| Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma | NCT00273910 | High-Risk Melan... | gp100:209-217 (... Montanide ISA-5... Imiquimod | 7 Years - | National Institutes of Health Clinical Center (CC) | |
| Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin | NCT00453050 | Melanoma (Skin) Metastatic Canc... | imiquimod indocyanine gre... flow cytometry immunologic tec... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and Cryosurgery | NCT01212562 | Basal Cell Carc... | Immunocryosurge... | 18 Years - | University of Ioannina | |
| Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma | NCT02242929 | Nodular Basal C... | Imiquimod 5% cr... Standard surgic... | 18 Years - 90 Years | Maastricht University Medical Center | |
| A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses | NCT01502020 | Actinic Keratos... | imiquimod cream... Vehicle Cream imiquimod cream... | 18 Years - | Actavis Mid-Atlantic LLC | |
| Efficacy of Tazarotene in Treatment of Verruca Plana | NCT05314127 | Warts Flat | Tazarotene 0.1%... Imiquimod Fluorouracil Cr... Petrolatum | 4 Years - | Zagazig University | |
| Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses | NCT00175643 | Actinic Keratos... | imiquimod | 18 Years - 75 Years | University of British Columbia | |
| Comparison of Treatment of Cervical Intraepithelial Lesions With Imiquimod or LLETZ | NCT04859361 | Intraepithelial... | Aldara 5% Topic... LLETZ | 18 Years - 40 Years | University Medical Centre Maribor | |
| Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma | NCT01400672 | Diffuse Intrins... | Tumor Lysate Va... Imiquimod Radiation thera... | 3 Years - | Masonic Cancer Center, University of Minnesota | |
| Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy | NCT02452307 | Recurrent Prost... | Peptide vaccine Montanide ISA-5... Granulocyte mac... Imiquimod mRNA Protamin local hyperther... | 45 Years - 80 Years | University Hospital Tuebingen | |
| Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases | NCT01421017 | Breast Cancer Metastatic Brea... Recurrent Breas... | Radiation Imiquimod Cyclophosphamid... | 18 Years - | NYU Langone Health | |
| Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma | NCT01403285 | Glioblastoma | Cyclophosphamid... IMA950 plus GM-... IMA950 Imiquimod | 18 Years - | Immatics Biotechnologies GmbH | |
| A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma | NCT03534947 | Basal Cell Carc... Basal Cell Carc... Skin Cancer Invasive Carcin... | Sonidegib Imiquimod Surgery Best supportive... | 18 Years - | Melanoma Institute Australia | |
| Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients | NCT01538901 | Actinic Keratos... | photodynamic th... imiquimod 5% cr... | 18 Years - 80 Years | Medical University of Vienna | |
| Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients | NCT01538901 | Actinic Keratos... | photodynamic th... imiquimod 5% cr... | 18 Years - 80 Years | Medical University of Vienna | |
| Imiquimod Treatment of High-grade CIN | NCT02917746 | Cervical Intrae... | Imiquimod Large Loop Exci... | 18 Years - 99 Years | Maastricht University Medical Center | |
| Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma | NCT01808820 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... High Grade Glio... | Dendritic Cell ... Tumor Lysate Imiquimod Leukapheresis | 13 Years - 99 Years | University of Miami | |
| Topical 5% Imiquimod Cream for Vulvar Paget's Disease | NCT02385188 | Paget Disease, ... | Imiquimod paracetamol lidocaine in Va... | 18 Years - | University Medical Center Nijmegen | |
| Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts | NCT00674739 | Genital Warts | Imiquimod 3.75% imiquimod... placebo cream | 12 Years - | Graceway Pharmaceuticals, LLC | |
| Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma | NCT03276832 | Metastatic Mela... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... | Imiquimod Biopsy Pembrolizumab Computed Tomogr... Positron Emissi... Magnetic Resona... | 18 Years - | Mayo Clinic | |
| Dendritic Cell Vaccine for Children and Adults With Sarcoma | NCT01803152 | Sarcoma Soft Tissue Sar... Bone Sarcoma | Dendritic Cells... Lysate of Tumor Gemcitabine Imiquimod Leukapheresis | 1 Year - 100 Years | University of Miami | |
| Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer | NCT00066872 | Non-melanomatou... | imiquimod conventional su... | - | National Cancer Institute (NCI) | |
| Comparing Immune Responses to Topical Imiquimod | NCT04809662 | Actinic Keratos... | Imiquimod | 18 Years - 85 Years | University of California, Davis | |
| Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna | NCT01088737 | Lentigo Maligna | Imiquimod | 18 Years - | Medical University of Graz | |
| Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma | NCT00273910 | High-Risk Melan... | gp100:209-217 (... Montanide ISA-5... Imiquimod | 7 Years - | National Institutes of Health Clinical Center (CC) | |
| Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment | NCT00941811 | HPV | Imiquimod | 18 Years - | Medical University of Vienna | |
| Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia | NCT00031759 | Cervical Cancer Precancerous Co... | imiquimod Ablative or exc... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses | NCT00175643 | Actinic Keratos... | imiquimod | 18 Years - 75 Years | University of British Columbia | |
| Aldara for the Treatment of Large and/or Multiple sBCC | NCT00189280 | Carcinoma, Basa... | Imiquimod | 18 Years - | Viatris Inc. | |
| Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients | NCT01538901 | Actinic Keratos... | photodynamic th... imiquimod 5% cr... | 18 Years - 80 Years | Medical University of Vienna | |
| Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma | NCT01808820 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... High Grade Glio... | Dendritic Cell ... Tumor Lysate Imiquimod Leukapheresis | 13 Years - 99 Years | University of Miami | |
| Comparison of Five Treatments in Patients With Plantar Warts | NCT01059110 | Plantar Warts | Salicylate oint... Imiquimod 5-Fluoro-Uracil Cryotherapy | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna | NCT01088737 | Lentigo Maligna | Imiquimod | 18 Years - | Medical University of Graz | |
| Gene and Protein Expression Profiles After Treatment of Actinic Keratoses | NCT05740969 | Actinic Keratos... | 5Fluorouracil Imiquimod Melatonin | 18 Years - | Zealand University Hospital | |
| CTCL Directed Therapy | NCT03116659 | Lymphoma, T-Cel... | Doxycycline Imiquimod | 30 Years - 89 Years | James J. Peters Veterans Affairs Medical Center | |
| Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | NCT02078648 | Adult Brain Gli... Glioblastoma Mu... | SL-701; poly-IC... Bevacizumab SL-701 + GM-CSF Imiquimod | 18 Years - | Stemline Therapeutics, Inc. | |
| Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses | NCT00777127 | Actinic Keratos... | Imiquimod Diclofenac | 18 Years - | Viatris Inc. | |
| Effect of Topical Imiquimod on Lentigo Maligna | NCT01161888 | Lentigo Maligna | Imiquimod | 45 Years - | University Hospital Birmingham NHS Foundation Trust | |
| Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma | NCT02242929 | Nodular Basal C... | Imiquimod 5% cr... Standard surgic... | 18 Years - 90 Years | Maastricht University Medical Center | |
| Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer | NCT02600949 | Metastatic Colo... Metastatic Panc... Stage IV Colore... Stage IV Pancre... Stage IVA Color... Stage IVB Color... | Imiquimod Pembrolizumab Sotigalimab Synthetic Tumor... Computed Tomogr... Magnetic Resona... | 18 Years - | M.D. Anderson Cancer Center | |
| Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer | NCT00079300 | Non-melanomatou... | imiquimod conventional su... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod | NCT01795313 | Ependymoma | HLA-A2 restrict... Imiquimod enzyme-linked i... flow cytometry immunohistochem... laboratory biom... | 12 Months - 21 Years | University of Pittsburgh | |
| Comparison of Treatment of Cervical Intraepithelial Lesions With Imiquimod or LLETZ | NCT04859361 | Intraepithelial... | Aldara 5% Topic... LLETZ | 18 Years - 40 Years | University Medical Centre Maribor | |
| Aldara for the Treatment of Large and/or Multiple sBCC | NCT00189280 | Carcinoma, Basa... | Imiquimod | 18 Years - | Viatris Inc. | |
| Imiquimod Treatment of CIN Lesions | NCT02329171 | Cervical Intrae... | Imiquimod LLETZ | 18 Years - | Maastricht University Medical Center | |
| Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma | NCT01264731 | Melanoma | MELITAC 12.1 Imiquimod | 18 Years - | University of Virginia | |
| Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts | NCT00674739 | Genital Warts | Imiquimod 3.75% imiquimod... placebo cream | 12 Years - | Graceway Pharmaceuticals, LLC | |
| Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) | NCT01453179 | Actinic Keratos... | Imiquimod Diclofenac | 18 Years - | Viatris Inc. | |
| Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer | NCT01909752 | Carcinoma, Non-... | Cyclophosphamid... DRibble vaccine Imiquimod GM-CSF HPV vaccine | 18 Years - | UbiVac | |
| Imiquimod Treatment of High-grade CIN | NCT02917746 | Cervical Intrae... | Imiquimod Large Loop Exci... | 18 Years - 99 Years | Maastricht University Medical Center | |
| Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV | NCT01663558 | Anal Dysplasia Human Papilloma... HIV | imiquimod ablative | 18 Years - | United States Naval Medical Center, San Diego | |
| Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor | NCT01171469 | Brain Tumor Glioblastoma Medulloblastoma Ependymoma Anaplastic Astr... | Dendritic Cells Imiquimod | - | Masonic Cancer Center, University of Minnesota | |
| A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ | NCT00189254 | Actinic Keratos... | Imiquimod | 18 Years - | Viatris Inc. | |
| CTCL Directed Therapy | NCT03116659 | Lymphoma, T-Cel... | Doxycycline Imiquimod | 30 Years - 89 Years | James J. Peters Veterans Affairs Medical Center | |
| Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts | NCT00189293 | Genital Warts | Imiquimod vehicle cream | 18 Years - | Viatris Inc. | |
| Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer | NCT00066872 | Non-melanomatou... | imiquimod conventional su... | - | National Cancer Institute (NCI) | |
| Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma | NCT01212549 | Basal Cell Carc... | Immunocryosurge... Cryoimmunothera... | 18 Years - 80 Years | University of Ioannina | |
| Intralesional 5-Fluorouracil (5FU), Topical Imiquimod Treatment for SCC | NCT03370406 | Carcinoma, Squa... | 5-fluorouracil Imiquimod 5% cr... | 18 Years - | University of Pittsburgh | |
| Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors | NCT01902771 | Glioma Brain Cancer Brain Tumor Glioblastoma Mu... High Grade Glio... | Dendritic Cell ... Tumor Lysate Imiquimod Leukapheresis | 1 Year - 29 Years | University of Miami | |
| Imiquimod Treatment of High-grade CIN | NCT02917746 | Cervical Intrae... | Imiquimod Large Loop Exci... | 18 Years - 99 Years | Maastricht University Medical Center | |
| The Real Life Topical Field Treatment of Actinic Keratosis Study | NCT02362152 | Actinic Keratos... | Ingenol mebutat... 5-fluorouracil Imiquimod Diclofenac | 18 Years - | LEO Pharma | |
| Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | NCT00118313 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim tetanus toxoid ... dimethyl sulfox... imiquimod adjuvant therap... | 12 Years - 120 Years | University of Virginia | |
| Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | NCT00118313 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim tetanus toxoid ... dimethyl sulfox... imiquimod adjuvant therap... | 12 Years - 120 Years | University of Virginia | |
| Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions | NCT02059499 | Anal Intraepith... High-grade Squa... HIV Infection | imiquimod fluorouracil questionnaire a... laboratory biom... | 21 Years - | AIDS Malignancy Consortium | |
| Real-world Evaluation of Diagnostic and Treatment Strategies in Low-Risk Basal Cell Carcinoma | NCT06252857 | Basal Cell Carc... | Imiquimod Topic... | 18 Years - | Maastricht University Medical Center | |
| Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis | NCT00948428 | Actinic Keratos... | imiquimod Aldara™ Vehicle Cream | 18 Years - | Actavis Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
